Spermidine Side Effects: What Studies Report

Spermidine is a naturally occurring polyamine found in human cells and in many foods. Interest in it as a supplement has grown faster than the clinical record, so questions about tolerability and adverse events usually run ahead of the published data. This page summarises what peer-reviewed papers and one preprint actually reported — the doses administered, the outcomes measured, and the gaps that remain. It does not interpret those findings as guidance for any individual.

This page is for educational purposes only and is not medical advice; consult a licensed physician before acting on any health information. Nothing below describes a protocol, and no dose appears here that is not attributed to a specific cited study.

Doses Used in Published Human Trials

Two randomized human trials anchor most discussion of spermidine tolerability, and they used doses that differ by more than fortyfold.

In a randomized clinical trial published in JAMA Network Open, researchers administered 0.9 mg/day of spermidine or placebo for 12 months to older adults with subjective cognitive decline and reported that the intervention did not significantly improve memory performance or the biomarkers assessed (PMID 35616942). That trial is the longest published human exposure period described in the verified literature summarised here, and its full account of tolerability and dropout is best read in the paper itself (PMID 35616942).

An exploratory double-blind randomized controlled trial supplemented older men with 40 mg/day of spermidine and reported minimal effects on circulating polyamine concentrations (PMID 39405978). That result matters for any safety discussion for a mechanical reason: the study reported that a dose far higher than the one used in the 12-month cognition trial did not translate into large measured shifts in blood polyamines (PMID 39405978), which complicates assumptions that oral intake maps neatly onto systemic exposure.

A pilot study in healthy older adults reported that spermidine mitigated markers of immune cell senescence and was associated with improved vaccine responses (PMID 42169618). Because researchers described it as a pilot, its sample size and duration limit what it can say about uncommon adverse events (PMID 42169618).

Human Trials at a Glance

Adverse Events in Human Trials: What Studies Report

The verified human literature summarised here is small, short, and concentrated in older adults. The 12-month randomized trial in subjective cognitive decline used 0.9 mg/day and its published report is the primary source for how investigators characterised participant experience over a year of daily intake (PMID 35616942). The exploratory trial in older men used 40 mg/day and focused its reported outcomes on circulating polyamine measurements rather than on a broad adverse-event catalogue (PMID 39405978).

Several consequences follow from that structure, and they are limitations rather than reassurances:

• Rare events cannot be detected. Trials sized for biomarker or cognitive endpoints, including the pilot study in healthy older adults (PMID 42169618), are too small to characterise infrequent adverse events.
• Populations are narrow. The published trials enrolled older adults (PMID 35616942) and older men (PMID 39405978), so they say nothing about younger people, pregnancy, or people with active disease.
• Exposure windows are short. Twelve months at 0.9 mg/day is the longest published human exposure described in this set (PMID 35616942); nothing in the verified record addresses multi-year use.
• Dose ranges are not bridged. No published trial in this set compared 0.9 mg/day (PMID 35616942) against 40 mg/day (PMID 39405978) head to head for safety endpoints.

What the 2022 Comprehensive Safety Review Compiled

A 2022 comprehensive review in Comprehensive Reviews in Food Science and Food Safety assembled the evidence base on spermidine across safety, health effects, absorption and metabolism, food-material evaluation, physical and chemical processing, and bioprocessing (PMID 35478379). Reviews of that kind are useful because they place supplement doses alongside ordinary dietary polyamine intake and alongside the absorption and metabolism data that determine whether ingested spermidine reaches tissues at all (PMID 35478379).

A review, however, inherits the limits of the studies inside it. Where primary human trials are few and short, a review cannot manufacture long-term adverse-event data; it can only describe what has been measured (PMID 35478379). Readers comparing supplement claims against the literature generally find the review's absorption and metabolism sections more informative than any single tolerability statement (PMID 35478379).

Animal and Cell Studies: What Studies Report

Most of what is known about spermidine's biological effects comes from non-human models, and those models were designed to test efficacy in disease states rather than to define human safety margins.

In one study, sustained oral spermidine supplementation rescued functional and structural defects in COL6-deficient myopathic mice (PMID 37528588). In another, spermidine treatment improved GRIN2B loss-of-function, described as a primary disorder of glutamatergic neurotransmission (PMID 40024627). A 2024 preprint reported that spermidine alleviated depression through control of the stress response (PMID 39677641); because that report was posted as a preprint, it had not completed peer review at the time of posting (PMID 39677641).

Findings like these are frequently cited in discussions of spermidine's promise. They are not tolerability data for people. Animal dosing, formulation, duration, and disease context differ from human supplementation, and none of these papers reported a human adverse-event profile (PMID 37528588, PMID 40024627).

Polyamine Metabolism Disorders and Why Context Matters

Polyamines are tightly regulated in human cells, and genetic disruption of that regulation produces recognisable disease. A 2024 review described Bachmann-Bupp syndrome, a disorder of polyamine metabolism, together with its treatment (PMID 37469105). The existence of a syndrome driven by dysregulated polyamine handling is the clearest illustration in this literature that polyamine levels are not a simple "more is better" axis (PMID 37469105).

That framing also explains why the exploratory trial's finding is interesting rather than disappointing: researchers reported that 40 mg/day produced minimal changes in circulating polyamines in older men (PMID 39405978), which is consistent with a system that defends its own set points.

Spermidine Synthase and Muscle Weakness in Cancer Models: What Studies Report

One 2025 study in Cell Metabolism is often misread in supplement discussions. Researchers reported that arachidonic acid triggered spermidine synthase secretion from a primary tumor and that this induced skeletal muscle weakness upon irradiation (PMID 40541182). The molecule under study there was the enzyme spermidine synthase released by tumor tissue in the context of radiation, not oral spermidine taken as a supplement (PMID 40541182).

The paper is worth knowing about for a narrower reason: it shows that polyamine-pathway activity can appear on the harmful side of a physiological ledger depending on tissue, signal, and setting (PMID 40541182). Extrapolating from it to supplement tolerability in healthy people would not be supported by what the study measured (PMID 40541182).

Plant and Food-Science Literature Does Not Address Human Tolerability

A large share of published spermidine research is agricultural. A 2019 review examined polyamines in halophytes, plants adapted to saline environments (PMID 31024603). A 2022 study described the physiological and biochemical bases of spermidine-induced alleviation of combined cadmium and lead stress in rice (PMID 36081232). A separate 2022 paper reported combined thermomechanical-biological treatment for valorizing corn by-products into added-value food and feed material (PMID 36432808).

These papers are legitimate science and are sometimes cited in consumer material as though they supported human claims. They do not. Plant stress physiology (PMID 36081232) and food-processing chemistry (PMID 36432808) measure outcomes in plants and processed materials, not adverse events in people.

What the Published Record Does Not Establish

• A defined human safety ceiling. The highest dose in the verified human trials summarised here was 40 mg/day in older men, and the study's reported focus was circulating polyamines (PMID 39405978).
• Long-term outcomes. The longest published exposure described here was 12 months at 0.9 mg/day (PMID 35616942).
• Interactions with medications or disease. None of the cited human reports were designed as interaction studies (PMID 35616942, PMID 39405978).
• Whether efficacy signals replicate. The pilot immune findings (PMID 42169618) and the depression preprint (PMID 39677641) have not been described as confirmed in larger peer-reviewed trials within this verified set.

Anyone weighing this literature should read the primary papers rather than summaries of summaries, and should discuss any personal health question with a licensed clinician. This page reports what researchers measured; it does not recommend, endorse, or discourage any use of spermidine.

References

• Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults With Subjective Cognitive Decline: A Randomized Clinical Trial (JAMA Network Open, 2022)
• Supplementation of spermidine at 40 mg/day has minimal effects on circulating polyamines: An exploratory double-blind randomized controlled trial in older men (Nutrition Research, 2024)
• A comprehensive review of spermidine: Safety, health effects, absorption and metabolism, food materials evaluation, physical and chemical processing, and bioprocessing (Comprehensive Reviews in Food Science and Food Safety, 2022)
• Spermidine Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults—A Pilot Study (Aging Cell, 2026)
• Sustained oral spermidine supplementation rescues functional and structural defects in COL6-deficient myopathic mice (Autophagy, 2023)
• Spermidine Treatment Improves GRIN2B Loss-Of-Function, A Primary Disorder of Glutamatergic Neurotransmission (Journal of Inherited Metabolic Disease, 2025)
• Spermidine alleviates depression via control of the stress response (bioRxiv, 2024)
• Bachmann-Bupp syndrome and treatment (Developmental Medicine and Child Neurology, 2024)
• Arachidonic acid triggers spermidine synthase secretion from primary tumor to induce skeletal muscle weakness upon irradiation (Cell Metabolism, 2025)
• Polyamines in Halophytes (Frontiers in Plant Science, 2019)
• Physiological and biochemical bases of spermidine-induced alleviation of cadmium and lead combined stress in rice (Plant Physiology and Biochemistry, 2022)
• Combined Thermomechanical-Biological Treatment for Corn By-Product Valorization into Added-Value Food (Feed) Material (Plants, 2022)